These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15380528)

  • 1. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.
    Vugmeyster Y; Kikuchi T; Lowes MA; Chamian F; Kagen M; Gilleaudeau P; Lee E; Howell K; Bodary S; Dummer W; Krueger JG
    Clin Immunol; 2004 Oct; 113(1):38-46. PubMed ID: 15380528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen.
    Harper EG; Simpson EL; Takiguchi RH; Boyd MD; Kurtz SE; Bakke AC; Blauvelt A
    J Invest Dermatol; 2008 May; 128(5):1173-81. PubMed ID: 18007580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
    Guttman-Yassky E; Vugmeyster Y; Lowes MA; Chamian F; Kikuchi T; Kagen M; Gilleaudeau P; Lee E; Hunte B; Howell K; Dummer W; Bodary SC; Krueger JG
    J Invest Dermatol; 2008 May; 128(5):1182-91. PubMed ID: 18239614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.
    Bonnekoh B; Böckelmann R; Pommer AJ; Malykh Y; Philipsen L; Gollnick H
    Skin Pharmacol Physiol; 2007; 20(2):96-111. PubMed ID: 17167274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efalizumab modulates T cell function both in vivo and in vitro.
    Koszik F; Stary G; Selenko-Gebauer N; Stingl G
    J Dermatol Sci; 2010 Dec; 60(3):159-66. PubMed ID: 21044829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
    Gottlieb AB; Krueger JG; Wittkowski K; Dedrick R; Walicke PA; Garovoy M
    Arch Dermatol; 2002 May; 138(5):591-600. PubMed ID: 12020219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.
    Bonnekoh B; Pommer AJ; Böckelmann R; Hofmeister H; Philipsen L; Gollnick H
    Skin Pharmacol Physiol; 2007; 20(5):237-52. PubMed ID: 17587888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efalizumab, a reversible T-cell modulator for psoriasis.
    Shear NH; Langley RG; Ho V
    J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroartemisinin ameliorates psoriatic skin inflammation and its relapse by diminishing CD8
    Chen Y; Yan Y; Liu H; Qiu F; Liang CL; Zhang Q; Huang RY; Han L; Lu C; Dai Z
    Theranostics; 2020; 10(23):10466-10482. PubMed ID: 32929360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-gamma preferentially reduces memory/effector CD8 T lymphocytes in healthy subjects.
    de Metz J; Out TA; Wever PC; Reijneke RM; Sprangers F; Sauerwein HP; Romijn JA; ten Berge IJ
    J Lab Clin Med; 1999 Aug; 134(2):147-53. PubMed ID: 10444028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling lymphocyte subpopulations in peripheral blood under efalizumab treatment of psoriasis by multi epitope ligand cartography (MELC) robot microscopy.
    Bonnekoh B; Malykh Y; Böckelmann R; Bartsch S; Pommer AJ; Gollnick H
    Eur J Dermatol; 2006; 16(6):623-35. PubMed ID: 17229602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.
    Lowes MA; Chamian F; Abello MV; Leonardi C; Dummer W; Papp K; Krueger JG
    BMC Dermatol; 2007 Feb; 7():2. PubMed ID: 17324275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis.
    Mortensen DL; Walicke PA; Wang X; Kwon P; Kuebler P; Gottlieb AB; Krueger JG; Leonardi C; Miller B; Joshi A
    J Clin Pharmacol; 2005 Mar; 45(3):286-98. PubMed ID: 15703364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
    Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
    Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis.
    Goedkoop AY; de Rie MA; Picavet DI; Kraan MC; Dinant HJ; van Kuijk AW; Tak PP; Bos JD; Teunissen MB
    Arch Dermatol Res; 2004 Apr; 295(11):465-73. PubMed ID: 14968366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.
    Ng CM; Joshi A; Dedrick RL; Garovoy MR; Bauer RJ
    Pharm Res; 2005 Jul; 22(7):1088-100. PubMed ID: 16028009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efalizumab].
    Descamps V
    Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):666-78. PubMed ID: 17053736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody.
    Dedrick RL; Walicke P; Garovoy M
    Transpl Immunol; 2002 May; 9(2-4):181-6. PubMed ID: 12180828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
    Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
    N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AsialoGM1+CD8+ central memory-type T cells in unimmunized mice as novel immunomodulator of IFN-gamma-dependent type 1 immunity.
    Kosaka A; Wakita D; Matsubara N; Togashi Y; Nishimura S; Kitamura H; Nishimura T
    Int Immunol; 2007 Mar; 19(3):249-56. PubMed ID: 17229818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.